Status:
COMPLETED
The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures
Lead Sponsor:
Istanbul University
Conditions:
Hip Fractures
Anemia
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
Hip fractures (HF) are the most common and serious pathology affecting the hip and are associated with a high mortality risk in elderly patients. The prevalence of HF is increasing day by day and surg...
Detailed Description
In the prospective randomized controlled study, a 6 - 12 month follow-up of participants undergoing hip fracture surgery with and without preoperative FCM treatment will be performed. Planning is bein...
Eligibility Criteria
Inclusion
- \>65 years
Exclusion
- \< 65 years
- Tumor-induced pathological fractures
- Patients undergoing preop ES replacement
- Ferric Carboxymaltose drug allergy
- Multiple trauma
- Receiving iron therapy in any form at the time of application
- Those who cannot come to postop clinical follow-up (out of town, etc.)
Key Trial Info
Start Date :
October 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 24 2025
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT06080893
Start Date
October 10 2023
End Date
March 24 2025
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul University, Istanbul Faculty of Medicine, Department Orthopaedics and Traumatology
Istanbul, Çapa / Fatih, Turkey (Türkiye), 34093